U.S. markets close in 39 minutes

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.76+0.42 (+5.72%)
As of 3:21PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close7.34
Open7.48
Bid7.83 x 1100
Ask7.84 x 1300
Day's Range7.35 - 8.45
52 Week Range1.08 - 24.90
Volume12,624,090
Avg. Volume15,732,893
Market Cap849.479M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.34
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 09, 2012
1y Target Est17.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021
    GlobeNewswire

    Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021. Conference Call Dial-In & Webcast Information:Date: Tuesday, March 2, 2021Time:4:30 PM Eastern TimeDomestic:877-407-0784International:201-689-8560Conference ID:13716984Webcast:http://public.viavid.com/index.php?id=143739 About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contacts Brant BiehnVaxart, Inc.650 550 3500IR@vaxart.comJoyce AllaireLifeSci Advisors, LLC617 435 6602jallaire@lifesciadvisors.com

  • How Risky Is Vaxart?
    Motley Fool

    How Risky Is Vaxart?

    Imagine a vaccine without the jab: That's Vaxart's specialty. The clinical-stage biotech company is developing oral vaccines for a variety of viruses -- including SARS-CoV-2, the virus that causes COVID-19. The company's shares soared more than 1,500% last year as Vaxart's investigational coronavirus vaccine made it through preclinical studies and began a human trial.

  • Top Small Cap Stocks for February 2021
    Investopedia

    Top Small Cap Stocks for February 2021

    These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.